Unraveling heterogeneity within ACPA-negative rheumatoid arthritis: the subgroup of patients with a strong clinical and serological response to initiation of DMARD treatment favor disease resolution.

Marloes VerstappenH W van SteenbergenP H P de JongA H M van der Helm-van Mil

Published in: Arthritis research & therapy (2022)

ACPA-negative RA patients with early DAS remission and a strong biomarker response (or baseline CRP levels ≥ 3× ULN) are most likely to achieve SDFR later on. This could guide personalized decisions on DMARD tapering/cessation in ACPA-negative RA.

Keyphrases

disease activity
rheumatoid arthritis
systemic lupus erythematosus
ankylosing spondylitis
interstitial lung disease
clinical trial
combination therapy
study protocol
smoking cessation
replacement therapy